Search

Author/Creator Fischer, J R

1. 1508TiPDurvalumab in frail and elder patients with stage four NSCLC: The DURATION trial. (23rd October 2018)

Authors:
Kuon, J; Bozorgmehr, F; Schneider, M A; Krisam, J; Lasitschka, F; Serke, M; Schuette, W; Moosmann, N; Gleiber, W; Faehling, M; Wermke, M; Schuett, P; Boesche, M; van Laak, V; Fischer von Weikersthal, L; Ulmer, M; Meyer zum Büschenfelde, C; Fischer, J R; Thomas, M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 92O Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817. (15th December 2019)

Authors:
Barlesi, F; Audigier-Valette, C; Felip, E; Ciuleanu, T-E; Jao, K; Rijavec, E; Urban, L; Aucoin, J-S; Zannori, C; Vermaelen, K; Frontera, O Arén; Ready, N; Curioni, A; Linardou, H; Poddubskaya, E; Fischer, J R; Pillai, R; Li, S; Acevedo, A; Paz-Ares, L
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 11
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search